Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Tissue-Specific Immunoregulation: A Call for Better Understanding of the "Immunostat" in the Context of Cancer.

Pao W, Ooi CH, Birzele F, Ruefli-Brasse A, Cannarile MA, Reis B, Scharf SH, Schubert DA, Hatje K, Pelletier N, Spleiss O, Reed JC.

Cancer Discov. 2018 Apr;8(4):395-402. doi: 10.1158/2159-8290.CD-17-1320. Epub 2018 Mar 15.

2.

Therapeutics targeting Bcl-2 in hematological malignancies.

Ruefli-Brasse A, Reed JC.

Biochem J. 2017 Oct 23;474(21):3643-3657. doi: 10.1042/BCJ20170080. Review.

PMID:
29061914
3.

Sphingosine kinase activity is not required for tumor cell viability.

Rex K, Jeffries S, Brown ML, Carlson T, Coxon A, Fajardo F, Frank B, Gustin D, Kamb A, Kassner PD, Li S, Li Y, Morgenstern K, Plant M, Quon K, Ruefli-Brasse A, Schmidt J, Swearingen E, Walker N, Wang Z, Watson JE, Wickramasinghe D, Wong M, Xu G, Wesche H.

PLoS One. 2013 Jul 5;8(7):e68328. doi: 10.1371/journal.pone.0068328. Print 2013.

4.

Measurement of Cancer Cell Growth Heterogeneity through Lentiviral Barcoding Identifies Clonal Dominance as a Characteristic of In Vivo Tumor Engraftment.

Nolan-Stevaux O, Tedesco D, Ragan S, Makhanov M, Chenchik A, Ruefli-Brasse A, Quon K, Kassner PD.

PLoS One. 2013 Jun 26;8(6):e67316. doi: 10.1371/journal.pone.0067316. Print 2013.

5.

Endoglin requirement for BMP9 signaling in endothelial cells reveals new mechanism of action for selective anti-endoglin antibodies.

Nolan-Stevaux O, Zhong W, Culp S, Shaffer K, Hoover J, Wickramasinghe D, Ruefli-Brasse A.

PLoS One. 2012;7(12):e50920. doi: 10.1371/journal.pone.0050920. Epub 2012 Dec 27.

6.

STK33 kinase activity is nonessential in KRAS-dependent cancer cells.

Babij C, Zhang Y, Kurzeja RJ, Munzli A, Shehabeldin A, Fernando M, Quon K, Kassner PD, Ruefli-Brasse AA, Watson VJ, Fajardo F, Jackson A, Zondlo J, Sun Y, Ellison AR, Plewa CA, San MT, Robinson J, McCarter J, Schwandner R, Judd T, Carnahan J, Dussault I.

Cancer Res. 2011 Sep 1;71(17):5818-26. doi: 10.1158/0008-5472.CAN-11-0778. Epub 2011 Jul 8.

7.

The growth factor Midkine antagonizes VEGF signaling in vitro and in vivo.

van der Horst EH, Frank BT, Chinn L, Coxon A, Li S, Polesso F, Slavin A, Ruefli-Brasse A, Wesche H.

Neoplasia. 2008 Apr;10(4):340-7.

8.

Rip2 participates in Bcl10 signaling and T-cell receptor-mediated NF-kappaB activation.

Ruefli-Brasse AA, Lee WP, Hurst S, Dixit VM.

J Biol Chem. 2004 Jan 9;279(2):1570-4. Epub 2003 Nov 24.

9.

Regulation of NF-kappaB-dependent lymphocyte activation and development by paracaspase.

Ruefli-Brasse AA, French DM, Dixit VM.

Science. 2003 Nov 28;302(5650):1581-4. Epub 2003 Oct 23.

Supplemental Content

Loading ...
Support Center